Tripos and Chronogen Announce a Drug Discovery Partnership
Tripos to Provide Complete Drug Discovery Chemistry Services to Chronogen
Tripos, Inc. and Chronogen Inc. announced a three-year collaboration to discover and optimize small-molecule therapeutics for cardiovascular disorders.
Under the agreement, Tripos will employ its knowledge-driven chemistry process to provide complete drug discovery chemistry services for Chronogen. Drawing upon its proprietary chemical libraries, expertise in data analysis, design tools and rapid synthetic follow-up capabilities, Tripos will support Chronogen's biological expertise in metabolic pathways related to aging. Chronogen will apply its proprietary in vivo screening technologies to rapidly select effective molecules, and Tripos will collaborate with Chronogen to optimize them for specific cardiovascular indications.
Most read news
Other news from the department science
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.